RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.
Develops, manufactures, and sells a broad range of biological based materials and services essential for the manufacture of diagnostic tests, commercial bioproduction of therapeutic drugs,including clinically annotated DNA and RNA.
Silicon Biosystems has developed a set of proprietary solutions called lab-on-a-chip technologies, targeted at miniaturized cell-biology testing. Silicon Biosystems exploits the microelectronics potential in order to produce miniaturized cellular biology laboratories.
Sirnaomics, Inc. is dedicated to becoming the leader in the RNAi technology focusing on (1) enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail; (2) improvement of the API delivery in vivo using clinical viable synthetic polymeric and lipid nanoparticles.
The company's technology involves the encapsulation, at room temperature, of active ingredients in micro- and nano-sized glass (silica) matrices as well as nanospheres utilizing a chemical process called sol-gel.
A drug delivery company developing enhanced and improved therapeutic medicines in several fields. Solubest is using advanced polymer formulations to prepare nanotransporters for drugs having delivery or compliance insufficiencies.
Sphere is commercializing picodroplet technology from Cambridge University that can perform thousands of simultaneous reactions on single cells and molecules contained within aqueous droplets, fractions of a millimeter in size. This platform enables diverse applications including: miniaturized profiling of drug candidates, generation of new biocatalysts and identification of novel algal strains.
SurModics® Synthetic ECM is a synthetic, stable, and scalable cell culture platform that provides an in vivo-like cell culture environment with its biomimetic extracellular matrix structure and surface. The technology produces results for cell research and cell-related applications. The nanofibrillar matrix utilizes Ultra-Web™ technology.
T2 Biosystems is creating a new generation of lab-quality diagnostic tools. Its technology is based on superparamagnetic nanoparticles. NanoDx particles have a superparamagnetic metal core surrounded by a polymer layer decorated by multiple analyte-specific binding agents. This nanoparticle platform can be used with a variety of binding agents such as antibodies, nucleic acids and small molecules.
The company specializes in the development, production, distribution and servicing of enabling solutions for the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Nanotechnology applications include a nanopipetting system.
Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell™ technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle.
Developed and manufactures a novel, biomaterial which utilizes hydrogel nanoparticles which aggregate to form a material of varying strength and elasticity which has extensive medical application including wound management and burn care, tissue regeneration and drug delivery devices.
The company sells nanowire sensing devices for molecular diagnostics - real-time, continuous flow and label free over 5 logs dynamic range to 10s of fm/mL sensitivity of proteins, nucleic acid and viruses. Virus LOD is single viruses.